Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
JA Solar appoints Peng Fang as new CEO
BEIJING, Jan. 26, 2010 (Xinhua News Agency) -- JA Solar Holdings Co. Ltd. (NASDAQ:JASO) (JASO.NASDAQ), a leading manufacturer of high-performance solar power (OTCBB:SOPW) products, announced the immediate appointment of Dr. Peng Fang as its new CEO on January 25.
The appointment will not affect Jin Baofang's position, who will continue to serve as executive chairman.
Peng joins JA Solar with more than 20 years of executive management experience under leading multinational tech companies in the solar and semiconductor industries in the US and China. (Edited by Yang Liu, yangliu@xinhua.org)
JA Solar appoints Peng Fang as new CEO
BEIJING, Jan. 26, 2010 (Xinhua News Agency) -- JA Solar Holdings Co. Ltd. (NASDAQ:JASO) (JASO.NASDAQ), a leading manufacturer of high-performance solar power (OTCBB:SOPW) products, announced the immediate appointment of Dr. Peng Fang as its new CEO on January 25.
The appointment will not affect Jin Baofang's position, who will continue to serve as executive chairman.
Peng joins JA Solar with more than 20 years of executive management experience under leading multinational tech companies in the solar and semiconductor industries in the US and China. (Edited by Yang Liu, yangliu@xinhua.org)
.142x.15 on 186k shares volume
Maybe some insiders are selling, might not be a bad thing, still need news on revenues and projects updates. Im holding long and think 2010 will be a good year for CSKH. Thx for the info!!
CSKH down 11%, not looking good. Tomorrow hopefully should be better. Just need some project news and revenues.
Entech Solar Launches the Entech Tubular Skylight
Entech Solar, Inc. (OTC BB: ENSL.OB) (the “Company”, “Entech Solar”) is pleased to announce the launch and immediate availability of its new Entech™ Tubular Skylight, a state-of-the-art tubular skylight developed based on Entech Solar’s patented Solar Collimator™ technology. This proprietary Solar Collimator is designed to provide superior optical efficiency, increase lumen output, and improve light distribution over conventional tubular skylights, providing enhanced all-day illumination in desired areas
The Entech Tubular Skylight is suitable for most commercial and industrial buildings that can benefit from natural daylighting, such as deep interior spaces of offices, warehouses, retail stores, manufacturing facilities, schools and hospitals. It can also contribute to a building meeting the certification requirements for the LEED® (Leadership in Energy and Environmental Design) Green Building Rating System, a nationally accepted benchmark for the design, construction, and operation of high performance green buildings
“Our tubular skylight captures daylight at the rooftop and delivers consistent daylight to interior spaces through an exclusive, patented tubular design,” explains Entech Solar’s Product Manager, Jim Lowell. “The Entech Tubular Skylight solves problems that can occur with conventional tubular skylights by taking sunlight from various angles during the day and year, and straightening the light as it reflects down the tube.” After installing skylights in the warehouse of Entech Solar’s corporate headquarters in Fort Worth, Texas-based AUI Contractors, Inc. is purchasing several for their own facility. AUI Director Matthew Wylie commented “We think this product is an excellent way to bring daylight into our own award-winning headquarters building and plan to recommend this product to our clients. Further, it contributes to our goal of LEED certification for this facility.” Entech Solar’s Chief Operating Officer, Sean Rooney, comments, “We are excited to launch Entech Solar’s innovative skylight product for sustainable and green building initiatives. The potential reduction in energy usage when natural daylight displaces the use of artificial lighting makes this product an important component of an organization’s overall energy-reduction strategy. It makes good business sense as well as being good for our environment.” The Entech™ Tubular Skylight is available for flat or sloped roofs. The tubing can be extended to accommodate most roof-to-ceiling distances. There is also an option suitable for buildings, offices or retail businesses that prefer open-grid ceilings. For more information on the Entech Tubular Skylight, please visit the Entech Tubular Skylight area of our website at www.entechsolar.com or contact Jim Lowell at 817-224-3509
About Entech Solar Entech Solar, Inc. is a leading developer of renewable energy technologies and sustainable daylighting solutions for the commercial, industrial and utility markets. Entech Solar designs concentrating solar modules that provide both electricity and thermal energy as part of its ThermaVolt™ product line and electricity only as part of the SolarVolt™ product line. The Company also manufactures and markets the Entech™ Tubular Skylight, a state-of-the-art tubular skylight that provides superior light output and optical efficiency for the commercial and industrial green building initiatives. For more information, please visit www.entechsolar.com
Very good insight, all solar stocks on my list are green today. A little correction is bound to take place here and there.
SOMX doing very well, HOD $2.98, currently trading $2.62, still may have a gap to fill from when it peaked $3.98 back in Dec. GLTY
CSKH closed Green today, took a hit yesterday. Most Solar stocks were Red today so this doesn't bother me. Its the marathon not a sprint.
Iv got MEVT on radar and at first glance the potential seems to out weigh any risk. Cheers!
SOMX News, trading up big AH's
Somaxon Provides Update on New Drug Application for Silenor® for the Treatment of Insomnia
SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today provided an update on the status of its New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.
“We believe that the dialogue we had with the FDA was constructive”
Somaxon held a meeting with senior leadership at the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the issues raised by the FDA in the Complete Response Letter Somaxon received in December 2009 relating to the Silenor NDA. The only remaining efficacy issue was related to the robustness of sustained subjective sleep maintenance efficacy in non-elderly adults with primary insomnia. In the meeting, the FDA and the company discussed this issue, and the agency instructed Somaxon to resubmit the contents of its January 20, 2010 pre-meeting briefing package to the FDA. The agency acknowledged that this resubmission would be considered a complete response to the Complete Response Letter Somaxon received in December. The FDA also agreed that this would be considered a Class 1 resubmission with a two-month review cycle. No additional safety or efficacy data was required to be included in the resubmission, and the company filed the resubmission with the FDA on January 21, 2010. As a result, the company anticipates a decision from the FDA by March 21, 2010.
“We believe that the dialogue we had with the FDA was constructive,” said Richard W. Pascoe, Somaxon’s president and chief executive officer. “We intend to continue to work diligently with the FDA during the two-month review cycle toward a potential approval for Silenor.”
In the meeting the FDA also reiterated that a revised Risk Evaluation and Mitigation Strategy (REMS), including a Medication Guide to be distributed with the product, will be required.
About Silenor®
Silenor is a low-dose (3 mg, 6 mg) oral tablet formulation of doxepin hydrochloride that is patent protected for use in insomnia. Physicians have prescribed doxepin for more than 35 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day. Based upon the controlled clinical trials of Silenor completed by Somaxon, the company believes that Silenor may be well tolerated by patients. In addition, the FDA has indicated that it will recommend that Silenor not be scheduled as a controlled substance.
About Somaxon Pharmaceuticals, Inc.
Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area.
For more information, please visit the company’s web site at www.somaxon.com.
FSNM looking sweet!! Heading over a buck soon.
MEVT news today and recent sure seems to set a nice stage for company growth. Anything I should look at specifically while I conduct DD?
mlkr, I sure hope you were holding, News out today and its looking good.
Yeah hard to say, It may need to fill some sort of gap tomorrow but where and when is the $$ question.
Wow i missed this one today, great job to those that got in early. It was bound to make that reversal anytime too. Oh well cant get them all.
Somaxon Provides Update on New Drug Application for Silenor® for the Treatment of Insomnia
SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today provided an update on the status of its New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.
“We believe that the dialogue we had with the FDA was constructive”
Somaxon held a meeting with senior leadership at the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the issues raised by the FDA in the Complete Response Letter Somaxon received in December 2009 relating to the Silenor NDA. The only remaining efficacy issue was related to the robustness of sustained subjective sleep maintenance efficacy in non-elderly adults with primary insomnia. In the meeting, the FDA and the company discussed this issue, and the agency instructed Somaxon to resubmit the contents of its January 20, 2010 pre-meeting briefing package to the FDA. The agency acknowledged that this resubmission would be considered a complete response to the Complete Response Letter Somaxon received in December. The FDA also agreed that this would be considered a Class 1 resubmission with a two-month review cycle. No additional safety or efficacy data was required to be included in the resubmission, and the company filed the resubmission with the FDA on January 21, 2010. As a result, the company anticipates a decision from the FDA by March 21, 2010.
“We believe that the dialogue we had with the FDA was constructive,” said Richard W. Pascoe, Somaxon’s president and chief executive officer. “We intend to continue to work diligently with the FDA during the two-month review cycle toward a potential approval for Silenor.”
In the meeting the FDA also reiterated that a revised Risk Evaluation and Mitigation Strategy (REMS), including a Medication Guide to be distributed with the product, will be required.
About Silenor®
Silenor is a low-dose (3 mg, 6 mg) oral tablet formulation of doxepin hydrochloride that is patent protected for use in insomnia. Physicians have prescribed doxepin for more than 35 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day. Based upon the controlled clinical trials of Silenor completed by Somaxon, the company believes that Silenor may be well tolerated by patients. In addition, the FDA has indicated that it will recommend that Silenor not be scheduled as a controlled substance.
About Somaxon Pharmaceuticals, Inc.
Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area.
For more information, please visit the company’s web site at www.somaxon.com.
What happened here, Closed $1.32, now trading $2.60's
SOMX wow, congrates to those that got in early. $2.79 currently
Holding ground today. Closed .15
Indeed, almost all but one are red now. Reversal may be imminent as we have seen some nice gains last few months, than we head up higher over next few weeks. GLTY
Took a hit last two days with a nice rebound today. Loaded and ready for a move back over a buck.
Solar stocks looking green again today.
http://finance.yahoo.com/q/cq?s=AKNS,ASTI,CSIQ,CSUN,EMKR,ENER,ESLR,FSLR,JASO,LDK,RSOL,SOL,SOLF,SPIR,SPWRA,STP,TSL,WFR,YGE&d=e
It certainly came off that .10 mark and is not looking like an up trend it our future. Solar will be a good place to be. Dont sell out too early, lots of gains to go around in 2010, AIMO
Anyone talked to the newly pointed IR? I called but no answer. He has a lot of of positive things to say on his twitter page.
Yes i noticed on the news out yesterday here on ihub showing him as a contact. Im sure he is being compensated now but from his twitter page he has been following the company for awhile. Stock took a little hit today, i did add at .16 and am very bullish with this stock. Hang tight for up coming news. I understand more news to follow.
Not sure about KNDR. Have any DD you want to share? Just looking at the chart it seems like its ready for a reversal.
Yes it was unexpected, not sure who sold like that and the bids fell out. Regardless its an opportunity to buy cheap imo. Last trade .16
IPO$, thanks for posting and i have to agree with your post. This is an undervalued Solar company imo, Solar is on the rebound and the key is to find an emerging one like cskh and hang on for the ride. Ducks seem to be in a row and they were hit like the rest with the financial crisis. I think it can only get better
I do own stock and this is AIMO
Our new IR for CSKH is Joe Noel, An Independent Stock Analyst and Public Relations for Small Cap Growth Companies.
CONTACT: Investor relations, Joe Noel, Emerging Growth Research, LLP for Clear Skies Solar, Inc., +1-925-922-2560
See him here,
http://twitter.com/jnoel701
Exactly, 2010 is looking great for Solar, just look at any solar stock chart and all are up huge, I think we may see some consolidate before the next leg up, but they will continue, CSKH is one that is undervalued IMHO. Good luck to you.
As the PR states, they have projects already lined up and ready to go once financing in place. Im loaded and feel very strongly that this us undervalued here, maybe .35 or .40 in the next 6 months I think is possible.
RSOL looking good, up 9% at $3.85
I saw it here on Ihub, if it wasnt its there now.
CSKH news:
Company Expecting Substantial Revenue Growth in 2010
MINEOLA, N.Y., Jan. 19 /PRNewswire-FirstCall/ --
Clear Skies Solar, Inc. (OTC:CSKH) (BULLETIN BOARD: CSKH) , a full-service renewable energy provider to commercial, industrial and agricultural clients, issued the following letter to its shareholders:
(Logo: http://www.newscom.com/cgi-bin/prnh/20090306/CSSLOGO )
Dear Fellow Shareholders:
As a new year begins, we would like to provide you with an update and perspective on the progress of Clear Skies Solar to position itself as a successful, sustainable and dynamic solar energy provider
As all of us are well aware, during the past 18 months there has been a considerable upheaval in many of the world's financial markets. Specifically, during much of 2009, there was a near complete freeze on capital for project and general financing for our clients. Without available credit in the markets, our clients had no means of closing on our contracts and we were not able to provide the Power Purchase Agreement (PPA) tool, which is a form of third-party financing that has driven the solar industry for many years. Of course, this situation significantly affected our revenue generation during the past year. Nonetheless, we are very happy to say that CSS was able to successfully navigate its way through the financial crisis, thereby avoiding the predatory and toxic lending practices that other firms have had to implement in order to complete client projects. In summary, we have kept our management team intact and our operations have remained strong
Only in the past few months has much changed as the economy in general, and the financial services sector in particular, is emerging from the recent global crisis. The credit markets are clearly starting to open-up and we now have several large projects which are in the final stages of approval and, while there can be no assurance of ultimate installation, we are very positive about the prospects for our future. In fact, we currently have more than $100 million of active proposals and are becoming increasingly positive relative to the conversion of a substantial portion of this into actual revenues to be posted during 2010
With the extension of the Federal Investment Tax Credit ("ITC") through 2016, the introduction of many state and local government incentives, record low solar module prices and general renewed interest in solar energy, the market environment for solar power implementation has, in our opinion, never been brighter. We are seeing considerable interest in new projects and it appears that many projects that had been placed on hold due to the financial crisis are now being restarted. As a result, we are expecting to realize considerable revenue growth during 2010
We would also like to reassure the shareholders that we are poised to take advantage of the above noted positive trends within the solar industry, which we believe will result in substantial near-term market share gains as we continue to deliver high quality solar projects throughout the expanding solar energy marketplace. We urge all of our shareholders to closely monitor our upcoming announcements. We believe 2010 will be an exciting year for Clear Skies Solar, Inc
Sincerely,
Ezra Green Chairman and Chief Executive Officer
http://www.newscom.com/cgi-bin/prnh/20090306/CSSLOGODATASOURCE: Clear Skies Solar, Inc
CONTACT: Investor relations, Joe Noel, Emerging Growth Research, LLP for
Clear Skies Solar, Inc., +1-925-922-2560
CSKH chart shows accumulation and I do expect it do continue and move up into the .20's
Disclaimer,
I do own stock
Quick DD
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45336060
Keep CSKH on radar, I expect news soon
I do own stock
Quick DD
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45336060
CSKH will continue up in the near term, Im adding as funds clear up and am very bullish
Disclaimer,
I do own CSKH stock